Beranda › Limfadenopati Immunoblastik › New York
Uji klinis Limfadenopati Immunoblastik di New York
5 studi untuk Limfadenopati Immunoblastik mencari peserta di lokasi di New York.
Kota di New York
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- dan 5 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06561048A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, New York
- Clinical Trial Site, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06393738A Registry for People With T-cell Lymphoma
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Weill Cornell Medical Center (Data Collection Only), New York
- dan 2 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 20 Mei 2026 · NCT05978141Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Columbia University, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2025 · NCT04234048Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.